Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes

References

• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care. 2016;39(Suppl 1):S1–S112.
   PubMed Web of Science ®Google Scholar
• Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613–1624.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Uehara Y, Okada S, et al. Contribution of fasting and postprandial hyperglycemia to hemoglobin A1c in insulin-treated Japanese diabetic patients. Endocr J. 2008;55:753–756.
   PubMed Web of Science ®Google Scholar
• Juarez DT, Ma C, Kumasaka A, et al. Failure to reach target glycated A1C levels among patients with diabetes who are adherent to their antidiabetic medication. Popul Health Manag. 2014;17:218–223.
   PubMed Web of Science ®Google Scholar
• Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 2004;17:183–190.
   Google Scholar
• Kilpatrick ES. Arguments for and against the role of glucose variability in the development of diabetes complications. J Diabetes Sci Technol. 2009;3:649–655.
   PubMedGoogle Scholar
• Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008;2:1094–1100.
   PubMedGoogle Scholar
• van Dijk JW, van Loon LJ. Exercise strategies to optimize glycemic control in type 2 diabetes: a continuing glucose monitoring perspective. Diabetes Spectr. 2015;28:24–31.
   PubMedGoogle Scholar
• International Diabetes Federation Guideline Development Group. Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract. 2014;103:256–268.
   PubMed Web of Science ®Google Scholar
• van Dijk JW, Manders RJ, Hartgens F, et al. Postprandial hyperglycemia is highly prevalent throughout the day in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93:31–37.
   PubMed Web of Science ®Google Scholar
• Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023–2029.
   PubMed Web of Science ®Google Scholar
• Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5:19–26.
   PubMedGoogle Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–885.
   PubMed Web of Science ®Google Scholar
• Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34:2508–2514.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia. 1996;39:1577–1583.
   PubMed Web of Science ®Google Scholar
• The DECODE study group on behalf of the Europe an Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–621.
   PubMed Web of Science ®Google Scholar
• Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–394.
   PubMed Web of Science ®Google Scholar
• Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga diabetes study. Diabetes Care. 2011;34:2237–2243.
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661–666.
   PubMed Web of Science ®Google Scholar
• Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32:221–226.
   PubMed Web of Science ®Google Scholar
• Leibson CL, Rocca WA, Hanson VA, et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann NY Acad Sci. 1997;826:422–427.
   PubMedGoogle Scholar
• Pochinka I, Strongin L, Struchkova J. Glycaemic variability and ventricular cardiac arrhythmias in type 2 diabetic patients with chronic heart failure (abstract 230). Diabetologia. 2012;55(Suppl 1):S102.
   Web of Science ®Google Scholar
• Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014;37:516–520.
   PubMed Web of Science ®Google Scholar
• Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19.
   PubMed Web of Science ®Google Scholar
• Xu F, Zhao LH, Su JB, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6:139.
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–1354.
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–2072.
   PubMed Web of Science ®Google Scholar
• Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging. 2000;17:411–425.
   PubMed Web of Science ®Google Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153–175.
   PubMed Web of Science ®Google Scholar
• Abrahamian H, Francesconi M, Loiskandl A, et al. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther. 2004;6:31–37.
   PubMedGoogle Scholar
• Uto Y, Teno S, Iwamoto Y, et al. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. Metabolism. 2002;51:20–24.
   PubMed Web of Science ®Google Scholar
• Islas-Andrade S, Revilla-Monsalve MC, Martinez de Hurtado E, et al. Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study. Pharmacology. 2003;68:89–95.
   PubMed Web of Science ®Google Scholar
• Kim MK, Suk JH, Kwon MJ, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011;92:322–328.
   PubMed Web of Science ®Google Scholar
• Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24:983–988.
   PubMed Web of Science ®Google Scholar
• Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002;18:484–490.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li H, Zhang X, et al. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in Chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther. 2013;15:481–488.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Anderson DM, Shelley S, et al. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:104–113.
   PubMed Web of Science ®Google Scholar
• Schatz H, Schoppel K, Lehwalder D, et al. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions. Exp Clin Endocrinol Diabetes. 2003;111:262–266.
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Van Acker KL, De Leeuw IH. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes Res Clin Pract. 2001;53:141–148.
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–163.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24:989–994.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract. 2002;55:221–227.
   PubMed Web of Science ®Google Scholar
• Blevins T. Control of postprandial glucose levels with insulin in type 2 diabetes. Postgrad Med. 2011;123:135–147.
   PubMed Web of Science ®Google Scholar
• Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:304–312.
   PubMed Web of Science ®Google Scholar
• Bretzel RG, Arnolds S, Medding J, et al. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004;27:1023–1027.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Del Prato S, Bue-Valleskey J, et al. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. J Diabetes Complications. 2007;21:20–27.
   PubMed Web of Science ®Google Scholar
• Gredal C, Rosenfalck A, Dejgaard A, et al. Optimal dose and timing of insulin aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes. Diabetes Res Clin Pract. 2008;80:293–298.
   PubMed Web of Science ®Google Scholar
• Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:446–454.
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:1008–1019.
   PubMed Web of Science ®Google Scholar
• Humalog (insulin lispro): US prescribing information. Indianapolis (IN): Eli Lilly and Company; 2015.
   Google Scholar
• Apidra (insulin glulisine): US prescribing information. Bridgewater (NJ): sanofi-aventis U.S. LLC; 2015.
   Google Scholar
• NovoLog (insulin aspart): US prescribing information. Plainsboro (NJ): Novo Nordisk Inc; 2015.
   Google Scholar
• Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838–848.
   PubMed Web of Science ®Google Scholar
• Fineman M, Weyer C, Maggs DG, et al. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504–508.
   PubMed Web of Science ®Google Scholar
• Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004;20:55–60.
   PubMed Web of Science ®Google Scholar
• Hinshaw L, Schiavon M, Mallad A, et al. Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and beta-cell function. Am J Physiol Endocrinol Metab. 2014;307:E494–E502.
   PubMed Web of Science ®Google Scholar
• Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks’ administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997;40:1278–1285.
   PubMed Web of Science ®Google Scholar
• Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care. 2003;26:3074–3079.
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724–730.
   PubMed Web of Science ®Google Scholar
• Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9:191–199.
   PubMed Web of Science ®Google Scholar
• Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30:2794–2799.
   PubMed Web of Science ®Google Scholar
• Riddle M, Pencek R, Charenkavanich S, et al. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32:1577–1582.
   PubMed Web of Science ®Google Scholar
• Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34(Suppl 2):S264–S271.
   PubMed Web of Science ®Google Scholar
• Balena R, Hensley IE, Miller S, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485–502.
   PubMed Web of Science ®Google Scholar
• Fineman MS, Shen LZ, Taylor K, et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411–417.
   PubMed Web of Science ®Google Scholar
• Ridge T, Moretto T, MacConell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:1097–1103.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250.
   PubMed Web of Science ®Google Scholar
• Byetta (exenatide) injection: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2015.
   Google Scholar
• Lyxumia (lixisenatide) 10 micrograms for injection: summary of product characteristics. Surrey (UK): Sanofi; 2016.
   Google Scholar
• Victoza (liraglutide): US prescribing information. Plainsboro (NJ): Novo Nordisk Inc; 2016.
   Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–278.
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–1230.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046–2055.
   PubMed Web of Science ®Google Scholar
• Bydureon (exenatide) injection: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2015.
   Google Scholar
• Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.
   PubMed Web of Science ®Google Scholar
• Trulicity (dulaglutide) injection: US prescribing information. Indianapolis (IN): Eli Lilly and Company; 2016.
   Google Scholar
• Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30:1095–1106.
   PubMed Web of Science ®Google Scholar
• Tanzeum (albiglutide) injection: US prescribing information. Wilmington (DE): GlaxoSmithKline LLC; 2016.
   Google Scholar
• Onglyza (saxagliptin) tablets: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2016.
   Google Scholar
• Januvia (sitagliptin) tablets: US prescribing information. Whitehouse Station (NJ): Merck & Co., Inc; 2016.
   Google Scholar
• Tradjenta (linagliptin) tablets: US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
   Google Scholar
• Farxiga (dapagliflozin) tablets: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2016.
   Google Scholar
• Invokana (canagliflozin) tablets: US prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc; 2016.
   Google Scholar
• Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11.
   PubMed Web of Science ®Google Scholar
• Jardiance (empagliflozin) tablets: US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc; 2016.
   Google Scholar
• Brodows RG, Qu Y, Johns D, et al. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin. 2008;24:1395–1397.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943–2952.
   PubMed Web of Science ®Google Scholar
• Diamant M, Nauck MA, Shaginian R, et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37:2763–2773.
   PubMed Web of Science ®Google Scholar
• FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973–981.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35:1225–1231.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hanefeld M, Shamanna P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications. 2014;28:386–392.
   PubMed Web of Science ®Google Scholar
• Ahren B, Gautier JF, Berria R, et al. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:861–868.
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13:1145–1154.
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234–2243.
   PubMed Web of Science ®Google Scholar
• Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4:53–61.
   PubMed Web of Science ®Google Scholar
• Frías JP, Nakhle S, Ruggles JA, et al. Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2016 Aug 16. [Epub ahead of print]. DOI:10.1111/dom.12763
   PubMed Web of Science ®Google Scholar
• Lind M, Hirsch IB, Tuomilehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015;351:h5364.
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–433.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Reinhardt RR, Carr MC. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes. Postgrad Med. 2016;128:391–397.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–4817.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Petrie JR, Sesti G, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231–241.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Vilsbøll T, Gallwitz B, et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32(Suppl 2):S223–S231.
   PubMed Web of Science ®Google Scholar
• Fonseca V, Zhu T, Karyekar C, et al. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14:365–371.
   PubMed Web of Science ®Google Scholar
• Stenlof K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355–2363.
   PubMed Web of Science ®Google Scholar
• Forst T, Uhlig-Laske B, Ring A, et al. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:542–550.
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Comenducci A, et al. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther. 2012;14:943–950.
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:67–76.
   PubMed Web of Science ®Google Scholar
• Chatterjee S. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study. J Diabetes. 2014;6:237–242.
   PubMed Web of Science ®Google Scholar
• Farngren J, Persson M, Schweizer A, et al. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:812–818.
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30:499–512.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16:613–621.
   PubMed Web of Science ®Google Scholar
• Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(Suppl 2):S276–S278.
   PubMed Web of Science ®Google Scholar
• Peene B, Benhalima K. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab. 2014;5:124–136.
   PubMedGoogle Scholar
• Salsali A, Hruba V, Ying L, et al. Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract 1104-P]. Diabetes. 2011;60:A303.
   Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–1478.
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–938.
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–447.
   PubMed Web of Science ®Google Scholar
• Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31:1119–1133.
   PubMed Web of Science ®Google Scholar
• Qiao Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201–205.
   PubMed Web of Science ®Google Scholar